This module allows you to check different measures of market premium (i. See a list of the most recent Stock Forum posts on Stockhouse. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. Montréal, Québec, Canada . Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Stockhouse. 2% for this period. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. 10% least volatile stocks in CA Market. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. Betteryear2. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. Theratechnologies Inc. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. 68 to a day high of $1. MONTREAL, Sept. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. 81 million for the quarter. Senior Director, Communications & Corporate Affairs. Theratechnologies Appoints New Board Member. Stockhouse. T. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share usage information with our partners. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . 's motion for leave to commence. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. 124. Stockhouse. 1. Investor Relations. Track Theratechnologies Inc. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage. 35 as of 10:41 a. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Cookies are used to offer you a better browsing experience and to. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. 2% per year. com uses cookies on this site. This news release constitutes a. MONTREAL, Oct. We also use them to share usage. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. Get the latest Sernova Corp (SVA) real. TH 48% v4,15M c1. Theratechnologies inc. 521. By continuing to use our service, you agree to our use of cookies. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. Agreement in principle on key amendments to loan. 25. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Denis Boucher. We also use them to share usage. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. The company was. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. By continuing to use our service, you agree to our use of cookies. 82 million. 57%) Q1 2020 Earnings Call. Further. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Further. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. By continuing to use our service, you agree to our use of cookies. com. NEW YORK, Dec. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business. 8 and 1. com uses cookies on this site. com uses cookies on this site. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. About SORT1+ Technology™ and TH1902. . (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. It is the Company’s proprietary. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. communications@theratech. Stockhouse. (TH. Register for your free account today at data. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. 05M. 6. 65 per cent to C$1. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. View real-time stock prices and stock quotes for a full financial overview. 72%. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. 9 million, adjusted EBITDA of $2. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. Share your ideas and get valuable. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). 4%. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. In the United States, Trogarzo ® (ibalizumab. Cookies are used to offer you a better browsing experience and to analyze our traffic. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 5000 0. Further. We currently market prescription products for people with HIV in the United States. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. - On track to meet FY2022. TH | October 13, 2022. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. US Headquarters. 4. 4 million. Theratechnologies to Announce Financial Results for Its First Quarter 2022. 9%, while the Biotechs industry saw earnings growing at 17. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We currently market prescription products for people with HIV in the United States. The abstract and poster can be found on Theratechnologies’ website. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage information with our partners. Cookies are used to offer you a better browsing experience and to analyze our. We also use them to share usage information with our partners. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. B2Gold Declares Fourth Quarter 2023 Dividend. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. ET. 617-356-1009. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. T. com uses cookies on this site. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. Browse posts by Sector and Subsector. Proceeds to Be Used to Redeem All of the Outstanding 5. TH | July 20, 2023. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. (THTX) Stock Price, Quote & News - Stock Analysis -20. 9% more than in 2021. com. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. . (882) posted 3 minutes ago. M. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. 86%. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. znewcar1. Biopharmaceutical company Theratechnologies Inc. Theratechnologies . Conjugating the short peptide with various anti-cancer agents allows for. com uses cookies on this site. 81 million for the quarter. US Headquarters. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. S. Find the latest Theratechnologies Inc. The company develops treatments for lipodystrophy . com. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. MONTREAL, Aug. MONTREAL, Feb. We also use them to share. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. 26 +15. 4. com uses cookies on this site. Theratechnologies layoffs. 49) by $0. Theratechnologies's earnings have been declining at an average annual rate of -35. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. By continuing to use our service, you agree to our use of cookies. 617-356-1009. is an employee of TaiMed Biologics USA, Inc. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. T. stock news by MarketWatch. H. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. 67, which is an increase of 1,144. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. 39 50-Day Range $0. By continuing to use our service, you agree to our use of cookies. Company Participants. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Stockhouse. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. The company had revenue of $20. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. com uses cookies on this site. Find more information. -986. We also use them to share usage. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our. Track Theratechnologies Inc. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies is pepped up on peptides. 33 +0. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 's motion for leave to commence. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. 5% workforce reduction. $44. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . Stockhouse. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. However, it did not meet the equivalence limits of 0. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. View real-time stock prices and stock quotes for a full financial overview. Stockhouse. - 2023 Q3 positive adjusted EBITDA to be. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. On average, they expect the company's stock price to reach $36. TH Stock Message Board for Investors. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. 02%. Theratechnologies inc. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. 33. Theratechnologies, Inc. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. m. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. com uses cookies on this site. 1M. Theratechnologies has generated ($1. By continuing to use our service, you agree to our use of cookies. . 04) earnings per share (EPS) for the quarter. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. com uses cookies on this site. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. Register for your free account today at data. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. 51 S1. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. The business had revenue of $27. Theratechnologies Inc. These companies provide a lot of detail to the OTC Markets Group including audited financials. MONTREAL, Aug. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. T. Theratechnologies Inc. MONTREAL, Oct. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. Stockhouse. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. During the last trading day the stock fluctuated 12. Stockhouse. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. 69, 1. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. - October 10, 2023) - KO Gold Inc. Stockhouse. FY2022 revenue. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. com uses cookies on this site. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. It's a different kind of fat that may require a different type of treatment. October 13, 2022 07:30 ET | Source: Theratechnologies. By continuing to use our service, you agree to our use of cookies. Theratechnologies reduces R&D head count to compensate for sales setback. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. “This is yet another major achievement for our oncology program. 63. MONTREAL, Sept. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Gary Littlejohn Stockhouse. Headquarters. By continuing to use our service, you agree to our use of cookies. MONTREAL, Nov. Theratechnologies Inc. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. 74M. GUD | Complete Knight Therapeutics Inc. sBLA for F8 formulation of tesamorelin submitted to FDA. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. Stockhouse. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. The business had revenue of $27. MONTREAL, Dec. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. stockhouse. Stockhouse. Theratechnologies inc. Stockhouse. Statut du système de négociation. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Watch list NEW Set a price target alert After Hours Last. Theratechnologies Inc. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource.